AzTrials
AzTrials

Multiple MyelomaPhase 2DPdNCT04124497

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

A Phase 2 study testing Daratumumab, Pomalidomide and Dexamethasone in people with Multiple Myeloma and Deletion 17P Syndrome, run by Fondazione EMN Italy Onlus at 15 sites in Italy.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Multiple myeloma (MM) with chromosome 17 deletion (del(17p) represents one of the most dangerous genetic variant of this disease, since it is associated with a high level of genomic instability. Del(17p) is present in approximately 10% of patients at diagnosis, and its frequency increases with disease evolution. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma, Deletion 17P Syndrome
What is being tested?
Daratumumab, Pomalidomide and Dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
15 sitesItaly
Study dates
1 Jul 2019to 1 Jul 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has given voluntary written informed consent
  • Subject must be at least 18 years of age.
  • Subject must have documented MM.
  • Subject must have del(17p) observed by FISH in at least 10% of bone marrow plasma cells at any time of MM history.
  • Subject must have serum monoclonal paraprotein (M-protein) level >=0.5 g/dL or urine M-protein, level >=200 mg/24 hours, or light chain MM, or serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
  • Subject must have received at least 1 and no more than 3 prior lines of therapy for MM.
Show all 18Show fewer
  • Subject must have received at least 2 consecutive cycles of lenalidomide in a previous line of therapy.
  • Subject must have achieved a response (PR or better) to at least one prior regimen.
  • Subjects must have either refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy.
  • Subject must have an ECOG Performance Status score of 0, 1, or 2.
  • Subject must have the following laboratory values:
  • Platelet count >=50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to drug administration).
  • Absolute neutrophil count (ANC) >= 1 x 109/L without the use of growth factors.
  • Corrected serum calcium <=14 mg/dL (3.5 mmol/L)
  • Alanine transaminase (ALT): <= 3 x the upper limit normal (ULN).
  • Total bilirubin: <= 2 x the ULN.
  • Calculated or measured creatinine clearance: >= 15 mL/minute
  • Females of childbearing potential (FBCP) must follow the Pregnancy Prevention Plan and use a highly effective and an additional barrier contraception method simultaneously for 28 days before starting pomalidomide, during treatment and dose interruptions, for at least 28 days after the last dose of pomalidomide and 3 months after the last dose of daratumumab Males must use an effective barrier method of contraception if sexually active with FCBP for at least 28 days before starting pomalidomide, during the treatment and dose interruptions, for at least 28 days after the last dose of pomalidomide and 3 months after the last dose of daratumumab. Male subjects must agree to refrain from sperm donation for at least 3 months after the last dose of daratumumab.

Who cannot join

  • Subject has received daratumumab or other anti-CD38 monoclonal antibody previously.
  • Subject's disease shows evidence of refractoriness or intolerance to pomalidomide. If previously treated with a pomalidomide-containing regimen, the subject is excluded if he or she:
  • Discontinued due to any adverse event related to prior pomalidomide treatment, or
  • If, at any time point, the subject was refractory to any dose of pomalidomide.
  • Refractory to pomalidomide is defined either:
  • Subjects whose disease progresses within 60 days of pomalidomide; or
Show all 19Show fewer
  • Subjects whose disease is nonresponsive while on lenalidomide. Nonresponsive disease is defined as either failure to achieve at least an MR or development of PD while on pomalidomide.
  • Subject has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization.
  • Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least 16 weeks prior to initiation of study treatment and are currently dependent on such treatment.
  • Subjects unable or unwilling to undergo antithrombotic prophylactic treatment.
  • Subject has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, in agreement with the medical monitor, is considered cured with minimal risk of recurrence within 3 years).
  • Subject has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second (FEV1) <60% of predicted normal), asthma, or a history of asthma within the last 2 years. Subjects with known or suspected COPD must have a forced expiratory volume (FEV) test during Screening.
  • Subject is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation positive).
  • Subject has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
  • Subject has clinically significant cardiac disease, including:
  • Myocardial infarction within 6 months before Cycle 1, Day 1, or unstable or
  • uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV)
  • Cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] Version 4 Grade 2 or higher) or clinically significant ECG abnormalities.
  • Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >500 msec.

Trial locations and contacts

15 sites in 1 country.

15 sites in 1 country

Italy15 sites

  • AOU Ospedali Riuniti Umberto I

    Ancona

  • Policlinico-Università degli Studi

    Bari

  • Ospedali Riuniti

    Bergamo

  • Policlinico S. Orsola

    Bologna

  • A.O. Spedali Civili di Brescia

    Brescia

  • AOU Policlinico Vittorio Emanuele

    Catania

  • Ospedale Niguarda Cà Grande

    Milan

  • Ospedale Maggiore

    Novara

  • Dipart. Di Medicina Interna e Scienze Biomediche

    Parma

  • Ospedale Oncologico Regionale

    Rionero in Vulture

  • Policlinico Umberto I - Università La Sapienza

    Roma

  • Istituto Clinico Humanitas

    Rozzano

  • A.O. Santa Maria

    Terni

  • AOU Città della Salute e della Scienza di Torino - Presidio Molinette

    Torino

  • Policlinico Universitario di Udine

    Udine

Other trials in Italy

About this study

Official title: Daratumumab, Pomalidomide and Dexamethasone for Del(17p) Positive Relapsed and Relapsed/Refractory Multiple Myeloma Patients [DEDALO]

Multiple myeloma (MM) with chromosome 17 deletion (del(17p) represents one of the most dangerous genetic variant of this disease, since it is associated with a high level of genomic instability. Del(17p) is present in approximately 10% of patients at diagnosis, and its frequency increases with disease evolution. The adverse prognosis of del(17p) has been observed in patients treated with conventional chemotherapy and new drugs. Only very few studies have suggested an advantage in treating del(17p) MM patients with specific therapies. In particular, several recent trials combining lenalidomide plus dexamethasone with a new agent, suggested that high risk cytogenetics patients may benefit from newest generation drugs. Yet, in all studies, outcome of patients with high risk genetic features have been derived from subgroup analyses, with all the limitations of this approach. To date no trial has been designed with the specific aim to test genotype-adapted therapies.

The objective of the present study is to evaluate the combination of daratumumab-pomalidomide-dexamethasone (DPd) in relapsed or relapsed/refractory MM patients harboring del(17p).

Read more

Treatment of relapsed or relapsed/refractory MM patients harbouring del(17p) is a relevant unmet medical need. A clinical trial designed to test a tailored treatment for this patient population would be a major improvement. In this perspective the combination DPd seems attractive since:

  • both daratumumab and pomalidomide are therapies not interfering with DNA replication, thus not increasing the intrinsic genomic instability of del(17p) plasma cells.
  • the POLLUX study has shown that daratumumab in combination with lenalidomide is highly effective in relapsed and relapsed/refractory MM patients.10
  • the IFM 2010-02 trial has suggested that pomalidomide may be effective in del(17p) patients.
  • the DPd combination has been successfully tested in MM patients with advanced disease.
Read the detailed description

Patients will undergo screening for protocol eligibility within 28 days (4 weeks) of enrolment.

After providing written informed consent to participate in the study, patients will be evaluated for study eligibility. It is to note that patients can be enrolled based on the presence of del(17p), as per center evaluation. However, the presence of del(17p) should be confirmed by the central laboratory (University of Torino laboratory), which will perform the test in 5 working days.

After registration, subjects who meet all the inclusion criteria will be treated according to the protocol, only after the presence of del(17p) has been confirmed by the central laboratory.

Treatment period includes administration of 28-day cycles of treatment with DPd until any sign of progression or intolerance.

The response will be assessed after each cycle. The LTFU period will start after development of confirmed progressive disease (PD) or treatment interruption due to toxicity. All patients are to be followed for survival during the LTFU period every 3 months via telephone or office visit.

Keywords
Multiple Myeloma, Monoclonal antibody, Immunomodulating agents
Medical subject headings
Multiple Myeloma, Chromosome 17 deletion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DaratumumabDrug

    Also called Darzalex

    • Daratumumab 16 mg/kg intravenously at following schedule:
    • cycle 1 and 2: days 1, 8, 15, and 22
    • cycle 3 through 6: days 1, and 15
    • from cycle 7 until disease progression: day 1.

  • PomalidomideDrug

    Also called Imnovid

    4 mg once daily on days 1-21

  • DexamethasoneDrug

    Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22

Study groups in NCT04124497
Study groupRoleWhat they receive
Daratumumab Pomalidomide dexamethasoneExperimentalTherapy consists in cycles of the DPd combination as follows: * Pomalidomide 4 mg once daily on days 1-21; * Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22; * Daratumumab 16 mg/kg intravenously at following schedule: * cycle 1 and 2: days 1, 8, 15, and 22 * cycle 3 through 6: days 1, and 15 * from cycle 7 until disease progression: day 1.
Receives: Drug: Daratumumab; Drug: Pomalidomide; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Minimal residual disease (MRD)

    Molecular minimal residual disease (MRD) 10-5 negativity rate assessed by means of next-generation sequencing (ClonoSEQ assay) in patients attaining a complete remission in the first year of treatment.

    Measured: 5 years

Secondary outcomes (8)

  1. Progression-free survival (PFS)

    Number of months from the date of randomization to the date of first observation of PD, or death from any cause as an event.

    Measured: 5 years

  2. Overall response rate (ORR)

    Overall response rate will include complete response (CR), very good partial response (VGPR) and partial response (PR) using the International Response Criteria. Responders are defined as subjects with at least a PR.

    Measured: 5 years

  3. Progression-free survival 2 (PFS2)

    Time from randomization to objective tumor progression on next-line treatment or death from any cause.

    Measured: 5 years

  4. Duration of response (DOR)

    Time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study.

    Measured: 5 years

  5. Overall survival (OS)

    Time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death.

    Measured: 5 years

  6. Safety as incidence of toxicities

    Severity of the toxicities will be graded according to the NCI CTC v.5 whenever possible. Laboratory data will be graded according to NCI CTC v.5 severity grade.

    Measured: 5 years

  7. Time to next therapy (TNT)

    Time to next therapy will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event.

    Measured: 5 years

  8. Percentage of patients with negative MRD and survival indices

    MRD negativity rate and survival might significantly change in particular subgroups of patients, that are defined on prognostic factors [ISS stage, additional cytogenetic abnormalities, previous treatment, presence of del(17p)]. Hence, subgroup analyses will be conducted.

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2019
  2. Study start1 Jul 2019
  3. Primary completion1 Jul 2027 (estimated)
  4. Study completion1 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04124497
Sponsor's protocol ID
DEDALO
Acronym
DPd
Status last verified
Sep 2026
First submitted
2 Jul 2019
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Daratumumab, Pomalidomide and Dexamethasone in people with Multiple Myeloma and Deletion 17P Syndrome, run by Fondazione EMN Italy Onlus at 15 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Minimal residual disease (MRD) (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04124497.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in